share_log

Canopy Growth | 10-Q: Q2 2025 Earnings Report

Canopy Growth | 10-Q: Q2 2025 Earnings Report

Canopy Growth | 10-Q：2025財年二季報
美股SEC公告 ·  2024/11/08 19:49

Moomoo AI 已提取核心訊息

Canopy Growth Corporation reported Q2 fiscal 2025 net revenue of $63.0 million, down 9% year-over-year, while net loss from continuing operations improved to $131.6 million from $148.2 million. Gross margin percentage increased to 35% from 34% in the prior year period.The revenue decline was primarily driven by lower Canadian adult-use cannabis sales of $18.4 million, down 24% year-over-year, partially offset by growth in medical cannabis and international markets. Storz & Bickel revenue increased 32% to $15.9 million on strong growth in Germany and the U.S. The company continued its cost reduction initiatives, with selling, general and administrative expenses decreasing 28% to $41.7 million.During the quarter, the company made progress on its balance sheet initiatives, including selling shares through its ATM program for gross proceeds of $92.2 million and amending its Credit Facility to extend the maturity date to December 2026. The company ended the quarter with $228.4 million in cash and cash equivalents. Management remains focused on achieving sustainable profitability through cost optimization and strategic growth initiatives.
Canopy Growth Corporation reported Q2 fiscal 2025 net revenue of $63.0 million, down 9% year-over-year, while net loss from continuing operations improved to $131.6 million from $148.2 million. Gross margin percentage increased to 35% from 34% in the prior year period.The revenue decline was primarily driven by lower Canadian adult-use cannabis sales of $18.4 million, down 24% year-over-year, partially offset by growth in medical cannabis and international markets. Storz & Bickel revenue increased 32% to $15.9 million on strong growth in Germany and the U.S. The company continued its cost reduction initiatives, with selling, general and administrative expenses decreasing 28% to $41.7 million.During the quarter, the company made progress on its balance sheet initiatives, including selling shares through its ATM program for gross proceeds of $92.2 million and amending its Credit Facility to extend the maturity date to December 2026. The company ended the quarter with $228.4 million in cash and cash equivalents. Management remains focused on achieving sustainable profitability through cost optimization and strategic growth initiatives.
Canopy Growth Corporation報告了2025財年第二季度淨營業收入爲$6300萬，同比下降9%，而持續經營的淨虧損從$14820萬改善至$13160萬。毛利率從去年同期的34%上升至35%。營業收入的下降主要是由於加拿大成人大麻銷售下降至$1840萬，同比下降24%，部分被醫療大麻和國際市場的增長所抵消。Storz & Bickel的營業收入增長了32%，達$1590萬，主要得益於在德國和美國的強勁增長。公司繼續推進成本削減措施，銷售、一般及行政費用下降28%，降至$4170萬。在這一季度，公司在資產負債表上取得了進展，包括通過其ATm計劃出售股份，獲得總收入$9220萬，並修訂其信貸設施，將到期日延長至2026年12月。公司在季度末的現金及現金等價物爲$22840萬。管理層仍然專注於通過成本優化和戰略增長舉措實現可持續盈利。
Canopy Growth Corporation報告了2025財年第二季度淨營業收入爲$6300萬，同比下降9%，而持續經營的淨虧損從$14820萬改善至$13160萬。毛利率從去年同期的34%上升至35%。營業收入的下降主要是由於加拿大成人大麻銷售下降至$1840萬，同比下降24%，部分被醫療大麻和國際市場的增長所抵消。Storz & Bickel的營業收入增長了32%，達$1590萬，主要得益於在德國和美國的強勁增長。公司繼續推進成本削減措施，銷售、一般及行政費用下降28%，降至$4170萬。在這一季度，公司在資產負債表上取得了進展，包括通過其ATm計劃出售股份，獲得總收入$9220萬，並修訂其信貸設施，將到期日延長至2026年12月。公司在季度末的現金及現金等價物爲$22840萬。管理層仍然專注於通過成本優化和戰略增長舉措實現可持續盈利。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Petros Pharmaceuticals
    PTPI
    -- 0.2930
    坎伯蘭藥業
    CPIX
    -- 5.150
    OptiNose
    OPTN
    -- 6.000
    Talphera
    TLPH
    -- 0.670
    BioAge Labs
    BIOA
    -- 4.790
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    多家機構看多！中國資產將全面重估：你會如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家機構唱好中國資產。 🎙️討論： 1. Deepseek引爆中國資產上漲，後市你怎麼看？ 2. 多家中國企業1月表現提升，你更看好誰？ 展开
    中國的資產重估引發熱議：牛友們在買什麼？